Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.53 |
| ▸ | CA1 | P00915 | 6/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13603846 | 0.87 | CA2 (0.51) | CA2CA1NAMPTTDP1MAPT | |
| SCHEMBL8125319 | 0.85 | L3MBTL1 (0.49) | CA2CA1NAMPTTDP1MAPT | |
| SCHEMBL6540486 | 0.83 | CA2 (0.49) | CA2CA1NAMPTNQO2CA12 | |
| SCHEMBL27741035 | 0.83 | CA2 (0.56) | CA2CA1NAMPTTDP1MAPT | |
| SCHEMBL572740 | 0.81 | IDO1 (0.60) | CA2CA1NAMPTMAPTCA12 | |
| SCHEMBL100146 | 0.80 | KDM4E (0.60) | CA2CA1NAMPTTDP1MAPT | |
| SCHEMBL1569661 | 0.80 | CA2 (0.56) | CA2CA1NAMPTTDP1MAPT | |
| SCHEMBL12283041 | 0.80 | NPC1 (0.60) | CA2CA1NAMPTTDP1MAPT | |
| SCHEMBL23449213 | 0.79 | CA2 (0.58) | CA2CA1NAMPTTDP1MAPT | |
| SCHEMBL5264226 | 0.79 | CA2 (0.58) | CA2CA1NAMPTTDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3290412-A1 | HIV-1 NUCLEOCAPSID INHIBITORS | Università degli Studi di Siena (IT) | 2018-03-07 | — | — | EP | disclosed |
| EP-3290412-A1 | HIV-1 NUCLEOCAPSID INHIBITORS | Università degli Studi di Siena (IT) | 2018-03-07 | — | — | EP | disclosed |
| US-7956060-B2 | Pyrimidine derivative compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-06-07 | — | — | US | disclosed |
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090012060-A1 | Antitumor Agent | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| EP-1749827-A1 | ANTI-TUMOR AGENT | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | CA2 4700/4885CA1 4120/4885NAMPT 2592/4885 |
| US-20090012060-A1 | Antitumor Agent | NR1H3, NR1I3, NR0B1 | CA2 2492/4885CA1 1239/4885NAMPT 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.